Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Avantogen Limited
Avantogen reports progress in trial of RP101 combined with chemotherapy for pancreatic cancer
July 4th, 2006
Avantogen Limited (ACU), of Sydney, Australia and San Diego, California, and Innovate Oncology, Inc., (IOVO), of New York, announced that two abstracts reporting on the evaluation of the use of RP101 in the treatment of patients with pancreatic cancer, were published at the American Society of Medical Oncology (ASCO) Meeting in Atlanta, Georgia. The first abstract (Fahrig et al, abstract no. 14000) reported the findings of a phase I pilot trial of 13 patients with advanced pancreatic cancer, which assessed the efficacy of RP101 in combination with gemcitabine and cisplatin, versus an appropriate historical control, consisting of patients who received the combination of...
Source: Pharma Law Weekly (2006-07-04)
|
